Anti-WNT2 monoclonal antibodies increase the activity of DCs in transplanted tumors in CRC mice, significantly improving the therapeutic efficacy of PD-1 antibodies(p = 0.0012) [63]. The gene discussed is WNT2; the disease is colorectal carcinoma.